Immunome Inc (NASDAQ:IMNM) price on Wednesday, April 30, rose 2.93% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $8.79.
A look at the stock’s price movement, the close in the last trading session was $8.54, moving within a range at $8.31 and $8.94. The beta value (5-Year monthly) was 2.059. Turning to its 52-week performance, $16.81 and $5.15 were the 52-week high and 52-week low respectively. Overall, IMNM moved 30.61% over the past month.
Immunome Inc’s market cap currently stands at around $764.83 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-18.
The average forecast suggests down to a -55.57% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 1.94M, representing a -78.53% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that IMNM is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend IMNM as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IMNM’s current price about 19.45% and 8.21% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 63.00, while 7-day volatility ratio is 5.79% and 9.51% in the 30-day chart. Further, Immunome Inc (IMNM) has a beta value of 2.01, and an average true range (ATR) of 0.61. Analysts have given the company’s stock an average 52-week price target of $33, forecast between a low of $23 and high of $35. Looking at the price targets, the low is -161.66% off current price level while to achieve the yearly target high, price needs to move -298.18%. Nonetheless, investors will most likely welcome a -275.43% jump to $33 which is the analysts’ median price.
If we refocus on Immunome Inc (NASDAQ:IMNM), historical trading data shows that trading volumes averaged 1.09 over the past 10 days and 1.22 million over the past 3 months. The company’s latest data on shares outstanding shows there are 87.01 million shares.
The 13.27% of Immunome Inc’s shares are in the hands of company insiders while institutional holders own 61.56% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 12.48 million on 2025-04-15, giving us a short ratio of 8.07. The data shows that as of 2025-04-15 short interest in Immunome Inc (IMNM) stood at 1492.0 of shares outstanding, with shares short rising to 9.52 million registered in 2025-03-14. Current price change has pushed the stock -17.23% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IMNM stock continues to rise going into the next quarter.
